期刊文献+

盐酸帕洛诺司琼在化疗性胃肠道反应防治中的应用 被引量:3

Value of Palonosetron Hydrochloride in the Prevention and Cure of Chemotherapy-related Gastrointestinal Reaction
下载PDF
导出
摘要 目的探讨盐酸帕洛诺司琼在恶性肿瘤化疗患者胃肠道反应防治中的应用价值。方法入组147例接受化疗的恶性肿瘤患者,随机分为2组,观察组77例在接受化疗的同时给予盐酸帕洛诺司琼联合地塞米松预防胃肠道反应的发生,而对照组70例仅给予地塞米松进行预防。比较观察化疗1周内2组患者的胃肠道反应发生情况。结果观察组患者的症状完全控制率为81.8%(63/77),不完全控制率为18.2%(14/77),对照组分别为52.9%(37/70)、47.1%(33/70),2组比较差异有统计学意义(P<0.05)。结论盐酸帕洛诺司琼用于化疗性胃肠道反应的防治安全有效,有利于化疗的顺利进行。 Objective To investigate the value of palonosetron hydrochloride in the prevention and cure of chem- otherapy-related gastrointestinal reaction in patients with malignant tumor. Methods The 147 patients with malignant tumor received chemotherapy were randomly divided into 2 groups, 77 cases of the observation group received palonosetron hydrochloride and dexamethasone at the same time, while 70 cases of the control group received dexa- methasone. The gastrointestinal reaction of the 2 groups were observed comparatively. Results The symptoms com- pletely control rate of the observation group was 81. 8% ( 63/77 ), the incomplete control rate was 18. 2% ( 14/77), those of the control group were 52.9% (37/70) and 47.1% ( 33/70), there was statistical significant difference between the 2 groups (P 〈 0.05). Conclusion palonosetron hydrochloride is safe and effective in the prevention and cure of chemotherapy-related gastrointestinal reaction.
作者 马福春
出处 《肿瘤基础与临床》 2013年第6期528-529,共2页 journal of basic and clinical oncology
关键词 盐酸帕洛诺司琼 化疗 恶性肿瘤 胃肠道反应 palonosetron hydrochloride chemotherapy malignant tumor gastrointestinal reaction
  • 相关文献

参考文献4

二级参考文献32

  • 1穆焱成.化疗引起恶心呕吐的药物治疗[J].实用癌症杂志,1996,11(4):286-288. 被引量:4
  • 2沈业寿,马金宝.亮菌研究的现状与展望[J].安徽大学学报(自然科学版),2007,31(1):82-86. 被引量:29
  • 3张文东,王秀问,陈振东,秦凤展,束永前,潘良熹,张茂宏.盐酸托烷司琼防治化疗药物所致消化道反应的多中心Ⅱ期临床试验[J].癌症,2007,26(8):870-873. 被引量:20
  • 4Grunberg SM, Deuson RR, Mavros P, et al. Incidence of c- hemotherapy-induced nausea and emesis after modern antie- metics[J]. Cancer,2004,100 ( 10 ) : 2261.
  • 5Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nau- sea and vomiting continue to reduce patients" quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment [J]. J Clin Oncol, 2006, 24 ( 27 ) : 4472.
  • 6Kris MG, Hesketh PJ, Somefield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology:up date 2006[J]. J Clin 0ncol,2006,24 ( 18 ) :2932.
  • 7Aapro MS. Palonosetron as an anti-emetic and anti-nausea a- gent in oncology[J]. Ther Clin Risk Manag, 2007,3 ( 6 ) : 1009.
  • 8Stohz R, Parisi S, Shah A, et al. Pharmacokinetics, metabo- lism and excretion of intravenous [14C]-palonosetron in healthy human volunteers[J]. Biopharm Drug Dispos,2004, 25(8) :329.
  • 9Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologicallynovel 5-HT3 receptor antagonist : results of a phase Ⅲ, sin- gle-dose trial versus dolasetron [J]. Cancer,2003,98 (11): 2473.
  • 10Wiser W,Berger A.Practical management of chemotherapy-induced nausea and vomiting[J].Oncology(Williston Park),2005,19(5):637-645.

共引文献13

同被引文献34

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部